At Asphalion, we are strongly committed to driving digitalization and integrating innovative tools to enhance our work. We believe that the thoughtful and responsible use of digital solutions, such as Artificial Intelligence, can significantly help improve project outcomes. That’s why we continuously explore new automation strategies to optimize our processes.
Continuing our revision of the different key authorities shaping the future of AI in healthcare we find the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. Recently, the MHRA shared a policy paper about the “Impact of AI on the regulation of medical products”.
The MHRA is reforming its regulatory framework to ensure proportionate oversight of AI-driven medical devices (AIaMD)—managing risk without stifling innovation. This positions the UK as a forward-thinking regulator in the global health tech landscape.
By integrating AI into its own regulatory processes, the MHRA aims to deliver faster, more efficient decisions, helping patients access safe, effective medical products sooner while freeing expert resources for high-priority work like innovation and public engagement.
Read the whole document here: https://bit.ly/4egcXAG
Need help in your regulatory endeavours? Contact us at: [email protected]
